TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24325104

Group type: EXPERIMENTAL
Intervention: HPC (hypoxia preconditioning)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 19874474

Group type: EXPERIMENTAL
Intervention: VKORC1 and CYP2C9 genotypes
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: INR and prior doses
Number of subjects: 223
Study: 18282607

Group type: EXPERIMENTAL
Intervention: Modified version of the 'Mother‐Infant Transaction Program' (intervention group of preterm infants)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group of preterm infants
Number of subjects: 145

Group type: COMPARATOR
Intervention: Healthy term infants (control group)
Number of subjects: 145
Study: 15984968

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg od
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg bid
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: cisapride 20 mg bid
Number of subjects: 512

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 512
Study: 12024137

Group type: EXPERIMENTAL
Intervention: Pediatric colonoscope (PCF‐100, Olympus)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard colonoscope (CF‐100L or CF‐Q140L, Olympus)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 10484598

Group type: EXPERIMENTAL
Intervention: Lower intensity cycling (6.3 +/- 1.7%)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Higher intensity cycling (13.3 +/- 3.8%)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Static handgrip at 2-3 min (3.8 +/- 1.1%)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Static handgrip at 4-5 min (8.6 +/- 2.8%)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Postexercise cuff occlusion (-5.5 +/- 1.2%)
Number of subjects: 18
Study: 8732108

Group type: EXPERIMENTAL
Intervention: ACNU, 5-Fu and ADM (Group B)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Me-CCNU, 5-Fu and ADM (Group A)
Number of subjects: 103
Study: 1672481

Group type: EXPERIMENTAL
Intervention: Celiprolol (200, 400, 600 mg once daily)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Propranolol (total daily dose 80, 160, 320 mg twice daily)
Number of subjects: 140
Study: 7151849

Group type: EXPERIMENTAL
Intervention: 10 cm visual analogue scale
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0‐10 point numerical rating scale
Number of subjects: 12

Group type: COMPARATOR
Intervention: four‐point verbal descriptive scale
Number of subjects: 12
Study: 31629570

Group type: EXPERIMENTAL
Intervention: dPly/PhtD vaccine (10 µg dPly and 10 µg PhtD) co-administered with 13-valent PCV (PCV13)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Placebo co-administered with 13-valent PCV (PCV13)
Number of subjects: 1803
Study: 27562778

Group type: EXPERIMENTAL
Intervention: Vitamin B12
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 25940212

Group type: EXPERIMENTAL
Intervention: Nucleus accumbens stimulation
Number of subjects: 4
Study: 23432056

Group type: EXPERIMENTAL
Intervention: Unattended speech with high intensity motivation words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unattended speech with low intensity motivation words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conversation depicting intrinsic motivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unintelligible conversation
Number of subjects: 0
Study: 21869692

Group type: EXPERIMENTAL
Intervention: 20 mg rimonabant
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 mg rimonabant
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19687793

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (LF) diet (20-25% of energy from fat, 60-65% from CHO)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate (HF) diet (40-45% of energy from fat, 40-45% from CHO)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (LF) diet
Number of subjects: 771
Study: 17894256

Group type: EXPERIMENTAL
Intervention: Full subsidization
Number of subjects: 132

Group type: COMPARATOR
Intervention: Partial subsidization
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Researcher monitoring
Number of subjects: 132

Group type: COMPARATOR
Intervention: Self monitoring
Number of subjects: 132
Study: 12621596

Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.2 micro g/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TRH (600 or 1200 micro g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Flumazenil (2 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pentagastrin (0.1 micro g/kg)
Number of subjects: 24
Study: 11188493

Group type: EXPERIMENTAL
Intervention: 0.56 g/kg of alcohol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9189784

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1415022

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN alpha) therapy
Number of subjects: 127
Study: 3893681

Group type: EXPERIMENTAL
Intervention: VP-16-213 (Group 1: n = 25)
Number of subjects: 81

Group type: COMPARATOR
Intervention: VP-16-213 + Cyclophosphamide (Group 2: n = 24)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: VP-16-213 + Doxorubicin (Group 3: n = 32)
Number of subjects: 81
Study: 31130429

Group type: EXPERIMENTAL
Intervention: Stenting for symptomatic vertebral artery stenosis
Number of subjects: 354

Group type: COMPARATOR
Intervention: Medical treatment for symptomatic vertebral artery stenosis
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Stenting for extracranial stenosis
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Stenting for intracranial stenosis
Number of subjects: 354
Study: 28264082

Group type: EXPERIMENTAL
Intervention: Advice to increase water intake to 8 cups per day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no advice to increase water intake)
Number of subjects: 38
Study: 25686399

Group type: EXPERIMENTAL
Intervention: High-dose oral tegafur-uracil (UFT) at 600 mg/day
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control group (no UFT treatment)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: High-dose oral tegafur-uracil (UFT)
Number of subjects: 309
Study: 22717130

Group type: EXPERIMENTAL
Intervention: Negative information pertaining to an anomalous experience (a card trick)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral information pertaining to an anomalous experience (a card trick)
Number of subjects: 0
Study: 21852010

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus radiation
Number of subjects: 681

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone
Number of subjects: 681
Study: 19951850

Group type: EXPERIMENTAL
Intervention: Diet and exercise habits (not specified in detail)
Number of subjects: 6600
Study: 17062772

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 12
Study: 15266763

Group type: EXPERIMENTAL
Intervention: Clotrimazole 200 mg vaginal tablets
Number of subjects: 223
Study: 11533342

Group type: EXPERIMENTAL
Intervention: Home nurse visit
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Hospital-based follow-up (control)
Number of subjects: 1014
Study: 9875578

Group type: EXPERIMENTAL
Intervention: Live recombinant canarypox-HIV-1 vaccine (given at days 0, 7, 14, and 21)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subunit gp120 vaccine (given at days 28 and 84)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unprimed controls (received two doses of subunit vaccine)
Number of subjects: 0
Study: 7612066

Group type: EXPERIMENTAL
Intervention: Zinc sulfate gel (Virudermin Gel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 2116311

Group type: EXPERIMENTAL
Intervention: Felodipine 5-10 mg b.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 353831

Group type: EXPERIMENTAL
Intervention: Mepiprazole
Number of subjects: 0
Study: 31959585

Group type: EXPERIMENTAL
Intervention: Medical cannabis (MC) users
Number of subjects: 128

Group type: COMPARATOR
Intervention: Non-MC users
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Frequent MC use
Number of subjects: 128
Study: 30239213

Group type: EXPERIMENTAL
Intervention: Xbox 360 Kinect cognitive games
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (range of motion exercises only)
Number of subjects: 44
Study: 27611958

Group type: EXPERIMENTAL
Intervention: Mobile app treatment (Tät®) focused on pelvic floor muscle training (PFMT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (postponed treatment)
Number of subjects: 123
Study: 26051508

Group type: EXPERIMENTAL
Intervention: Personalized Feedback Interventions (PFIs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 23481667

Group type: EXPERIMENTAL
Intervention: Shang Ring device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dorsal slit technique
Number of subjects: 0
Study: 21649839

Group type: EXPERIMENTAL
Intervention: Fixed-dose amlodipine/olmesartan medoxomil (AML/OM) 5/20 mg, uptitrated to AML/OM 5/40 mg and 10/40 mg
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Fixed-dose amlodipine/olmesartan medoxomil + hydrochlorothiazide (HCTZ) 10/40+25 mg
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Ambulatory BP monitoring substudy (n=243)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 999
Study: 19656039

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study: 16918857

Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 736

Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 736
Study: 12673155

Group type: EXPERIMENTAL
Intervention: Ginseng (400 mg.d‐1 of G115; equivalent to 2 g of Panax ginseng C.A. Meyer root material)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 38
Study: 10201761

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Droperidol 20 microg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg/kg
Number of subjects: 120
Study: 9552520

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: BENESTENT‐I study
Number of subjects: 0

Group type: COMPARATOR
Intervention: BENESTENT‐II pilot study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phase IV of the BENESTENT‐II pilot study
Number of subjects: 0
Study: 1988829

Group type: EXPERIMENTAL
Intervention: Intravenous vidarabine (30 mg/kg/day for 10 days)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Acyclovir (30 mg/kg/day for 10 days)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Vidarabine in babies with disease confined to the skin, eyes, or mouth
Number of subjects: 202

Group type: COMPARATOR
Intervention: Acyclovir in babies with disease confined to the skin, eyes, or mouth
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Vidarabine in babies with encephalitis
Number of subjects: 202

Group type: COMPARATOR
Intervention: Acyclovir in babies with encephalitis
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Vidarabine in babies with disseminated disease
Number of subjects: 202

Group type: COMPARATOR
Intervention: Acyclovir in babies with disseminated disease
Number of subjects: 202
Study: 6984223

Group type: EXPERIMENTAL
Intervention: Cardioplegic arrest and continuous cross‐clamping of aorta
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ischaemic arrest and intermittent cross‐clamping of aorta
Number of subjects: 40
Study: 3987791

Group type: EXPERIMENTAL
Intervention: 50 mg moclobemide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 100 mg moclobemide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200 mg moclobemide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31594772

Group type: EXPERIMENTAL
Intervention: South Gloucestershire pain and opioid review service
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GP recommendations for funding and clinical supervision
Number of subjects: 18
Study: 29278869

Group type: EXPERIMENTAL
Intervention: Glenohumeral stabilization exercise (GSE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scapular stabilization exercise (SSE)
Number of subjects: 40
Study: 27055414

Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops, once daily
Number of subjects: 246

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops
Number of subjects: 246
Study: 24616308

Group type: EXPERIMENTAL
Intervention: Docetaxel plus prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rising CTC count from day 0 to 21
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline CTC counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding day-0 CTCs to baseline PSA and other covariates
Number of subjects: 0
Study: 22999671

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate mouthwash
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 35
Study: 20354275

Group type: EXPERIMENTAL
Intervention: 10-core prostate biopsy scheme
Number of subjects: 304

Group type: COMPARATOR
Intervention: sextant biopsy scheme
Number of subjects: 304
Study: 19192859

Group type: EXPERIMENTAL
Intervention: Cocaine contingency (four prize draws for each cocaine-negative urine)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Opiate-cocaine contingency (one draw for each urine negative for opiates or cocaine, four draws if negative for both)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Opiate-cocaine contingency
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cocaine contingency
Number of subjects: 67
Study: 15852492

Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) 30 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14607390

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (sertraline, phenelzine, or bupropion) for 8 weeks
Number of subjects: 28
Study: 12884887

Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d) plus buprenorphine (12 mg/d)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d) plus methadone (65 mg/d)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo plus buprenorphine (12 mg/d)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo plus methadone (65 mg/d)
Number of subjects: 180
Study: 8730616

Group type: EXPERIMENTAL
Intervention: Bifidobacterium sp fermented milk with placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bifidobacterium sp fermented milk with inulin (18g/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 12
Study: 1986877

Group type: EXPERIMENTAL
Intervention: Survival probabilities displayed at bedside and staff viewed a videotape on measurement of survival probabilities and costs of pediatric intensive care.
Number of subjects: 436

Group type: COMPARATOR
Intervention: Control group (patients did not receive survival probabilities but healthcare workers viewed the videotape).
Number of subjects: 436
Study: 6355500

Group type: EXPERIMENTAL
Intervention: Early excision and grafting
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nonoperative treatment with silver sulfadiazine cream
Number of subjects: 47
Study: 31917447

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intensive lifestyle weight loss intervention (LWLI)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: LAGB
Number of subjects: 61

Group type: COMPARATOR
Intervention: LWLI
Number of subjects: 61
Study: 31393319

Group type: EXPERIMENTAL
Intervention: Doctor‐Office Collaborative Care (DOCC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 8
Study: 30362939

Group type: EXPERIMENTAL
Intervention: Emollient bath additives plus standard eczema care
Number of subjects: 482

Group type: COMPARATOR
Intervention: Standard eczema care alone (no bath additives)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 482
Study: 27499517

Group type: EXPERIMENTAL
Intervention: Ocriplasmin 0.125 mg
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 220
Study: 25411291

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 751

Group type: COMPARATOR
Intervention: Non-breastfeeding
Number of subjects: 751
Study: 23171800

Group type: EXPERIMENTAL
Intervention: NOYA biodegradable polymer sirolimus-eluting stent
Number of subjects: 300

Group type: COMPARATOR
Intervention: FIREBIRD2 durable polymer sirolimus-eluting stent
Number of subjects: 300
Study: 20210907

Group type: EXPERIMENTAL
Intervention: Football training group (FTG, two 1-hour sessions per week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (doctoral advice group, DAG)
Number of subjects: 25
Study: 17935929

Group type: EXPERIMENTAL
Intervention: Peer-delivered intervention (enhanced intervention [EI])
Number of subjects: 923

Group type: COMPARATOR
Intervention: Standard human immunodeficiency virus education (standard intervention [SI])
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 923
Study: 16006259

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (folic acid 5 mg, pyridoxine 40 mg, cyanocobalamin 1 mg once daily for 3 months)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No vitamin treatment (control group)
Number of subjects: 93
Study: 12450955

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 10390316

Group type: EXPERIMENTAL
Intervention: Oral nimodipine (30 mg every 6 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8683244

Group type: EXPERIMENTAL
Intervention: High dose (HD) cisplatin 100 mg/m2
Number of subjects: 159

Group type: COMPARATOR
Intervention: Low dose (LD) cisplatin 50 mg/m2
Number of subjects: 159
Study: 1839703

Group type: EXPERIMENTAL
Intervention: Medtronic plasma TFE
Number of subjects: 51

Group type: COMPARATOR
Intervention: Gore-Tex polytetrafluoroethylene (PTFE)
Number of subjects: 51
Study: 6666695

Group type: EXPERIMENTAL
Intervention: Self-help program delivered via a written manual and limited duration phone calls
Number of subjects: 0
Study: 30344172

Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia with tramadol
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia with hydromorphone
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia with ropivacaine
Number of subjects: 1230
Study: 27338717

Group type: EXPERIMENTAL
Intervention: Collagen sponge coated with human coagulation factors (test group, n=44)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (n=47)
Number of subjects: 91
Study: 25247318

Group type: EXPERIMENTAL
Intervention: Erlotinib dose escalation (150 mg, increasing by 50 mg every 2 weeks, maximum 250 mg)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard-dose erlotinib (100 mg per day)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Erlotinib dose escalation
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard-dose erlotinib
Number of subjects: 146
Study: 23015113

Group type: EXPERIMENTAL
Intervention: Clopidogrel (n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clopidogrel vs. Placebo (delta values)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: VerifyNow® response
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thrombus area in hypo-responders vs. good responders
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thrombus area in T2DM vs. non-diabetic patients
Number of subjects: 90
Study: 20965851

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (facial mask ventilation)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Invasive ventilation (mechanical ventilation by tracheal intubation or tracheal incision)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Invasive ventilation
Number of subjects: 56
Study: 17917555

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Aripiprazole (10-30 mg/day)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 253

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 253
Study: 16180181

Group type: EXPERIMENTAL
Intervention: Propafenone (150‐300 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amiodarone (150‐450 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both Propafenone and Amiodarone
Number of subjects: 40
Study: 12187545

Group type: EXPERIMENTAL
Intervention: L-arginine glutamate (6 g) plus yohimbine HCl (6 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: yohimbine alone (6 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 10442189

Group type: EXPERIMENTAL
Intervention: Postoperative RT and concomitant bolus FU administration with additional chemotherapy (FU 600 mg/m2/week x 6 + LV 500 mg/m2/week x 6) followed by pelvic RT with FU (400 mg/m2) during RT
Number of subjects: 220

Group type: COMPARATOR
Intervention: Postoperative RT and concomitant FU only
Number of subjects: 220
Study: 7617181

Group type: EXPERIMENTAL
Intervention: Copolymer 1 (20 mg daily subcutaneous injection for 2 years)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Copolymer 1
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 2774639

Group type: EXPERIMENTAL
Intervention: Grenz rays administered once weekly for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14